Mineralys Therapeutics Inc
MLYS
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.41B
Close$
$2.56
90.2% downside
Current Fair Value
90.2% downsideOvervalued by 90.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.41 Billion |
|---|---|
| Enterprise Value | $2.30 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.29 |
| Beta | 0.65 |
| Outstanding Shares | 82,834,752 |
Return
| Return on Equity | -23.78% |
|---|---|
| Return on Assets | -23.25% |
| Return on Invested Capital | -26.22% |
Valuation & Multiples
| P/E Ratio | -13.34 |
|---|---|
| PEG | 196.09 |
| Price to Sales | - |
| Price to Book Ratio | 3.73 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -13.74 |
| Enterprise Value to Net Income | -16 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.55
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 18, 2026
EPS Estimate
$-0.54
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 104.90% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 28.21%▼ 105.29% |
|---|---|
| Total Invested | $630.53M▼ 74.32% |
| Investors Holding | 64▼ 165.00% |
ESG Score
No data